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Key Points
• LL37 primes platelet
function and augments
thrombus formation.
• LL37 mainly acts
through FPR2/ALX in
platelets.
Platelet-associated complications including thrombosis, thrombocytopenia, andhemorrhage
are commonly observed during various inﬂammatory diseases such as sepsis, inﬂammatory
bowel disease, and psoriasis. Despite the reported evidence on numerous mechanisms/
molecules that may contribute to the dysfunction of platelets, the primary mechanisms
that underpin platelet-associated complications during inﬂammatory diseases are not fully
established. Here, we report the discovery of formyl peptide receptor 2, FPR2/ALX, in
platelets and its primary role in the development of platelet-associated complications via
ligation with its ligand, LL37. LL37 acts as a powerful endogenous antimicrobial peptide,
but it also regulates innate immune responses. We demonstrate the impact of LL37 in the
modulation of platelet reactivity, hemostasis, and thrombosis. LL37 activates a range of
platelet functions, enhances thrombus formation, and shortens the tail bleeding time in
mice. By utilizing a pharmacological inhibitor and Fpr2/3 (an ortholog of human FPR2/ALX)–
deﬁcient mice, the functional dependence of LL37 on FPR2/ALX was determined. Because the
level of LL37 is increased in numerous inﬂammatory diseases, these results point toward a
critical role for LL37 and FPR2/ALX in the development of platelet-related complications in
such diseases. Hence, a better understanding of the clinical relevance of LL37 and FPR2/ALX in
diverse pathophysiological settings will pave the way for the development of improved
therapeutic strategies for a range of thromboinﬂammatory diseases.
Introduction
Platelets play pivotal roles in the regulation of hemostasis; however, their unwarranted activation
under pathological conditions leads to the formation of blood clots (thrombosis) within the circulation,
which is a major cause of premature death.1-3 Platelets also play significant roles in the regulation of
innate immunity, inflammatory responses, and microbial infection.4,5 The activation of platelets during
inflammatory diseases induces the formation of blood clots or disseminated intravascular coagulation in
capillaries, resulting in the blockage of blood supply to tissues.6,7 Moreover, platelet activation results in
the aggregation and sequestration of platelets, instigating thrombocytopenia.8,9 Several mechanisms
that contribute to platelet dysfunction under inflammatory diseases have been reported10; however, the
primary molecular mechanisms that underpin platelet activation are not fully understood.
LL37 is the only cathelicidin known to be expressed in human cells.11 It acts as a powerful antimicrobial
peptide against bacteria,12 fungi,13 and viral particles14 and modulates innate and adaptive immune
responses predominantly through formyl peptide receptor 2 (FPR2/ALX).15,16 Despite detailed
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research on the roles of LL37 in the modulation of inflammatory
responses in various pathological settings,17,18 its effects in the
regulation of thrombosis and other platelet-related complica-
tions remained unknown for a long time. Because the level of
LL37 released during inflammation is significantly higher than
normal,19,20 understanding its critical functions in the modulation
of platelet reactivity will pave the way for determining fundamental
mechanisms underlying platelet-related complications in various
inflammatory diseases. Immediately prior to the submission of
this manuscript, Pircher et al21 demonstrated the ability of LL37
to prime circulating platelets and induce thromboinflammation.
Although they have established a significant functional impact of
LL37 in platelets, its actions via FPR2/ALX were not determined.
In this study, we report the effects of LL37 on a range of platelet
functional assays and establish its roles in the modulation of
platelet reactivity, thrombosis, and hemostasis. Moreover, by using
pharmacological tools and Fpr2/3-deficient mice, we have
established the functional dependence of LL37 on FPR2/ALX in
platelets.
Methods
The University of Reading Research Ethics Committee approved all
the experimental procedures using human blood from healthy
volunteers. The mouse strains of Fpr12/222 and Fpr2/32/223 on
a C57BL/6 background obtained from William Harvey Research
Institute (London, United Kingdom) and control C57BL/6 mice
from Envigo (United Kingdom) were used in this study. Detailed
methods for the preparation of platelets, immunoblotting, enzyme-
linked immunosorbent assay (ELISA), immunocytochemistry, in vitro
thrombus formation, tail bleeding, platelet aggregation, dense granule
secretion, platelet spreading, calcium mobilization, cytotoxicity and
flow cytometry-based assays, mass spectrometry, molecular docking,
and statistical analyses are provided in the supplemental Methods.
Results
Platelets store LL37 and release it upon activation
The expression of LL37 has been reported in several cell types
including neutrophils where it is mainly stored in granules.24,25 By
using immunofluorescence microscopy, we determined the pres-
ence of LL37 in human platelets (Figure 1A). Furthermore, resting
and cross-linked collagen-related peptide (CRP-XL) (a glycoprotein
VI [GPVI]-selective agonist) (1 mg/mL)–activated human platelets
were centrifuged, and the supernatant and pellet were used in
ELISA to determine the release of LL37 from platelets. In the resting
state, the level of LL37 was significantly higher in the pellet (15596
433 pM) compared with the supernatant (41 6 12 pM) (Figure 1B).
However, upon activation of platelets with CRP-XL, the presence of
LL37was significantly increased in the supernatant (14906581.7 pM)
compared with the pellet (59 6 7.6 pM). Similar results were
obtained upon the activation of platelets with collagen (acts via GPVI
and integrin a2b1) or TRAP-6 (acts via PAR1). To corroborate these
results, the release of LL37 in human platelet-poor plasma (PPP) or
platelet-rich plasma (PRP) was investigated by mass spectrometry.
The level of LL37 was stable and significantly increased in PRP
compared with PPP over 2 hours, indicating its release; by contrast,
the level of LL37 was significantly reduced in PPP (Figure 1C).
Together, these data confirm the presence of LL37 in platelets
(between picomolar and nanomolar concentrations) and its release
upon platelet activation.
LL37 augments thrombus formation and
affects hemostasis
To determine whether LL37 has a direct influence on thrombotic
complications during inflammatory diseases, its effects on thrombus
formation under arterial flow conditions were investigated.26,27
LL37 (10, 20, and 50 mM) significantly increased the thrombus
formation (Figure 1Di) and the mean fluorescence intensity in a
concentration-dependent manner (Figure 1Dii). The highest con-
centration of LL37 (50 mM) increased the thrombus intensity by
;70% compared with the vehicle-treated samples (Figure 1Diii).
Moreover, LL37 affected hemostasis in mice as determined by a tail
bleeding assay. A mean bleeding time of 370.8 6 46.6 seconds
was observed in the vehicle-treated group; however, the infusion
of LL37 significantly shortened the bleeding time to a mean of
225.2 6 18.8 seconds (Figure 1E).
LL37 induces platelet activation
To further determine the impact of LL37 in distinctive platelet
functions, additional assays were performed. Human isolated
platelets were treated with a vehicle or LL37 (5, 10, and 20 mM),
and the level of aggregation was monitored by optical aggregometry.
LL37 directly induced platelet aggregation in a concentration-
dependent manner, notably, 20 mM LL37 induced 100% aggrega-
tion (Figure 1F). In line with a recent study,21 in our experiments, LL37
failed to induce aggregation in human PRP (supplemental Figure 1).
Similarly, to determine whether LL37 influences inside-out signaling
to integrin aIIbb3 and a-granule secretion, the level of fibrinogen
binding and P-selectin exposure was measured respectively
using human isolated platelets and PRP by flow cytometry. LL37
increased the level of fibrinogen binding in human isolated
platelets (Figure 2Ai) and PRP (Figure 2Aii) in a concentration-
dependent manner. Similarly, the level of P-selectin exposure was
increased by LL37 in isolated platelets (Figure 2Bi) and PRP
(Figure 2Bii). Moreover, the ability of LL37 to induce plate-
let spreading on immobilized fibrinogen (Figure 2C) was
analyzed as a marker for integrin aIIbb3-mediated outside-in
signaling. LL37 (5, 10, and 20 mM) significantly increased the
number of adhered (Figure 2Ci) and spread (Figure 2Cii) platelets,
and the relative surface area (Figure 2Ciii) compared with their
controls. Furthermore, to assess the effects of LL37 in calcium
mobilization, intracellular calcium levels were measured in human
isolated platelets. LL37 induced calcium mobilization with a
maximum level achieved with 50 mM. The level of calcium release
obtained with 50 mM LL37 is similar to that obtained with CRP-XL
(1 mg/mL), although the initial kinetics of calcium release
appeared to be faster for LL37 (Figure 2D). These data confirm
that LL37 triggers distinctive platelet functions.
LL37 does not exhibit cytotoxic effects in platelets
A previous study28 reported the inhibitory effects of LL37 in platelets
at exceptionally high concentrations (0.1-1.2 mM). It has been shown
previously that LL37 exhibits cytotoxic effects in neutrophils and
monocytes at concentrations higher than 50 mM.29 To determine
whether the concentrations of LL37 used in this study (#50 mM)
exhibit any cytotoxic effects in platelets, lactate dehydrogenase
cytotoxicity assay was performed. The concentrations of LL37 used
here (1-50 mM) failed to exert any cytotoxic effects in human isolated
platelets, although 100 mM LL37 displayed significant toxicity
(Figure 2E). These results confirm that LL37 concentrations up to
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50 mM do not display any toxic effects in platelets, although higher
concentrations may exhibit cytotoxic effects.
LL37 activates platelets selectively through FPR2/ALX
Numerous studies indicate that LL37 acts primarily through
FPR2/ALX to exert its effects in immune cells.16,30,31 The expression
of FPR2/ALX in megakaryocytes and human and mouse platelets at
the transcript level has been reported previously.32,33 Here, the
presence of FPR2/ALX in human platelets remained unchanged in
resting and CRP-XL (1 mg/mL)–activated platelets as confirmed by
immunoblots (Figure 3Ai), although the activation increased the surface
level as determined by flow cytometry (Figure 3Aii). Moreover, the
presence of Fpr2/3 (an ortholog to human FPR2/ALX) in control, and its
absence in Fpr2/32/2 mouse platelets, was confirmed (Figure 3Aiii).
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Figure 1. Presence of LL37 in platelets and its impact on thrombus formation, hemostasis, and platelet activation. (A) Human platelets were treated with primary
antibodies against LL37 and appropriate fluorescent-labeled secondary antibodies (purple) and phalloidin (green) and analyzed by confocal microscopy (magnification 3100;
bar represents 10 mm). Images shown are representative of 3 independent experiments. (B) the level of LL37 in resting and activated (1 mg/mL CRP-XL, 1 mg/mL collagen or
10 mM thrombin receptor activator peptide 6 [TRAP-6]) platelet pellets and supernatants (SNs) was measured by ELISA using LL37-selective antibodies. Data represent
mean 6 standard error of the mean (SEM) (n 5 5). (C) The stability/release of LL37 in human plasma was analyzed by mass spectrometry (liquid chromatography mass
spectrometry [LC-MS]). Graph represents the intensities of LL37 (100 mg/mL) spiked in PRP and PPP at different time points over 120 minutes. Control represents the
intensity of LL37 at 100 mg/mL (unspiked). Data represent mean 6 SEM (n 5 3). (D) The effects of LL37 in the modulation of thrombus formation. Human DiOC6-labeled
whole blood was preincubated with a scrambled peptide (SC) or LL37 (10, 20, and 50 mM) for 10 minutes prior to perfusion over collagen-coated (400 mg/mL) Vena8
Biochips. Images (i) (at 10 minutes) shown are representative of 3 separate experiments (magnification 310; bar represents 10 mm). Data (ii-iii) represent mean 6 SEM
(n 5 3). (E) The impact of LL37 (20 mM) on the modulation of hemostasis. C57BL/6 mice (10-12 weeks old) were anesthetized 20 minutes before the infusion of a scrambled
peptide or LL37 (20 mM) via femoral artery 5 minutes before the dissection of 1 mm of tail tip, and monitoring of time to cessation of bleeding. Data represent mean 6 SEM
(n 5 6 per group). (F) The effects of LL37 on platelet activation were measured by optical aggregometry using human isolated platelets. Data represent mean 6 SEM (n 5 6).
The statistical significance was established by 1-way analysis of variance (ANOVA) followed by Bonferroni’s correction in most of the experiments except the data shown
in panels B and E, which were analyzed by 2-tailed unpaired Student t test and nonparametric Mann-Whitney U test, respectively (*P , .05; **P , .01).
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To determine the functional dependence of LL37 on FPR2/ALX, the
binding of LL37 to the platelet surface was confirmed using a
fluorescently labeled LL37 (5-FAM-LC-conjugated LL37) by flow
cytometry. 5-FAM-LL37 (20 mM) displayed marked binding to the
surface of human platelets compared with a fluorescently labeled
scrambled LL37 (5-FAM-conjugated sc-LL37) (Figure 3Bi). Similarly,
LL37 (20 mM) binding was analyzed using platelets obtained from
control, Fpr1-, or Fpr2/3-deficient mice. The control and Fpr12/2
mouse platelets exhibited significant binding to 5-FAM-LL37 com-
pared with Fpr2/32/2 (Figure 3Bii). In addition to LL37, mCRAMP
(mouse ortholog of LL37) was also investigated for the binding to
mouse platelets, and indeed, the level of mCRAMP binding was
reduced in Fpr2/32/2 mouse platelets compared with the controls
(Figure 3Biii). The interactions between LL37 and FPR2/ALX were
examined by molecular docking analysis, which predicted that LL37
peptide forms prominent hydrogen bonds with key residues such as
Gln-89, Ser-182, Asn-285, and Gly-275 of FPR2/ALX that are
identified as crucial for receptor activation (Figure 3Biv; Table 1).
The functional dependence of LL37 on FPR2/ALX was analyzed by
using a range of platelet functional assays. The activatory effects of
LL37 (5-50 mM) were substantially reduced in Fpr2/32/2 mouse
platelets both in isolation (Figure 3Ci,Di) or whole blood
(Figure 3Cii,Dii) compared with the controls as analyzed by
fibrinogen binding and P-selectin exposure. Notably, the character-
ization of platelets obtained from Fpr2/32/2mice failed to display any
defects in size and number of platelets or the levels of major platelet
receptors such as GPVI (Figure 3Ei), glycoprotein Iba (GPIba)
(Figure 3Eii), aIIbb3 (Figure 3Eiii), and a2b1 (Figure 3Eiv) compared
with the control mouse platelets. To corroborate these results,
platelet functional assays were performed in the presence of a
selective FPR2/ALX antagonist, WRW4 (WRWWWW), in human
and mouse platelets. The addition of WRW4 (5 mM) in human
isolated platelets before activation with 20 mM LL37 inhibited platelet
aggregation by ;40% (Figure 3F). Similarly, the effects of LL37
(20 mM) on fibrinogen binding (Figure 3Gi) and P-selectin exposure
(Figure 3Gii) were significantly reduced in WRW4 (5 mM)–treated
mouse platelets. These data demonstrate the involvement of FPR2/
ALX in the regulation of LL37-mediated effects in platelets.
FPR2/ALX regulates normal platelet activation
To validate the importance of FPR2/ALX in the regulation of normal
platelet activation, further experiments were performed using human
isolated platelets in the presence or absence of WRW4. CRP-XL
(0.25 mg/mL)–induced platelet aggregation was significantly
reduced in the presence of WRW4 (2.5-20 mM). The inhibition of
FPR2/ALX with WRW4 (20 mM) reduced the platelet aggregation
by ;89% (Figure 4A). Similar results were obtained with adenosine
59-diphosphate (ADP)–induced platelet aggregation, wherein
WRW4 (20mM) inhibited 75% of aggregation (Figure 4B). Moreover,
dense granule secretion (evidenced by adenosine triphosphate
release) was significantly reduced in the presence of WRW4
(Figure 4C). The platelet activation was also assessed using whole
blood obtained from control and Fpr2/32/2 mice upon stimulation
with conventional platelet agonists such as CRP-XL, ADP, AY-NH2
(activates protease activated receptor, PAR4), and U46619, an
analog of thromboxane A2 by measuring the levels of fibrinogen
binding and P-selectin exposure. Similar to human platelets, the
activation of platelets obtained from Fpr2/32/2mice upon stimulation
with CRP-XL (Figure 4D), ADP (Figure 4E), AY-NH2 (Figure 4F),
and U46619 (Figure 4G) was significantly reduced compared
with the controls. Additionally, preincubation of human platelets
with WRW4 (1.25-20 mM) significantly decreased the number of
adhered (Figure 5Ai) and spread (Figure 5Aii) platelets, and the relative
surface area (Figure 5Aiii). The impact of Fpr2/3 on the modulation of
hemostasis in mice was determined by tail bleeding assay. A mean
bleeding time of 428.5 6 64.8 seconds was observed in the control
group; however, Fpr2/3-deficient mice significantly increased the
bleeding time to a mean of 1128 6 71.9 seconds (Figure 5B).
Together, these data emphasize the impact of FPR2/ALX on the
regulation of normal platelet function through a positive feedback
mechanism (may be through LL37), and thus the inhibition or deletion
of this receptor results in diminished platelet function in general.
FPR2/ALX exerts its effects through
cAMP-dependent signaling
FPRs are Gi-coupled receptors,
34 which are known to inhibit adenylate
cyclase, reducing the level of cAMP, a known inhibitor of platelet
function. Therefore, the deletion of Gi-coupled receptor genes in mice
increases the basal cAMP levels in target cells.35,36 To investigate
whether the inhibition of FPR2/ALX in human or deletion of Fpr2/3 in
mouse platelets is influenced by the cAMP-dependent signaling, the
level of cAMP was quantified in platelets. The inhibition of FPR2/ALX
with WRW4 (20 mM) significantly elevated the cAMP levels com-
pared with the controls in human platelets (Figure 5Ci). Similarly,
resting Fpr2/32/2 mouse platelets exhibited elevated basal levels of
cAMP comparedwith the controls (Figure 5Cii). In order to corroborate
this data, we investigated the phosphorylation of the vasodilator-
stimulated phosphoprotein (VASP), a substrate for protein kinase
A that is involved in the regulation cAMP-mediated signaling. The
treatment of platelets with an FPR2/ALX-selective inhibitor, WRW4,
increased the phosphorylation of Ser157-VASP (Figure 5Di).
Similarly, Fpr2/32/2 mouse platelets demonstrated increased
phosphorylation of Ser157-VASP compared with control mouse
platelets (Figure 5Dii).
Discussion
LL37 is a powerful antimicrobial peptide that plays substantial roles
in the initiation of chemotaxis and subsequent inflammatory
Figure 2. The impact of LL37 on platelet activation, spreading, and calcium mobilization. (A) The level of fibrinogen binding was analyzed using fluorescein
isothiocyanate–conjugated fibrinogen antibodies by flow cytometry in human isolated platelets (i) or PRP (ii). (B) Similarly, the level of P-selectin exposure was measured in
human isolated platelets (i) or PRP (ii) using PECy5-labeled P-selectin antibodies. Data represent mean 6 SEM (n 5 3). (C) Platelet adhesion and spreading on immobilized
fibrinogen was analyzed using platelets treated with LL37 (5, 10, and 20 mM) by confocal microscopy (magnification 360; bar represents 10 mm). The number of adhered (i)
and spread (ii) platelets, and the relative surface area of spread platelets (iii) was determined via analyzing the images using ImageJ. Ten random fields of view were recorded
and analyzed for each sample. Data represent mean 6 SEM (n 5 3). (D) Ca21 mobilization was measured using Fluo-4 AM dye-loaded human isolated platelets upon
stimulation with LL37 by spectrofluorimetry. Data represent mean of maximum level of Ca21 6 SEM (n 5 4). (E) The cytotoxic effects of LL37 were measured in human
isolated platelets using a lactate dehydrogenase cytotoxicity assay kit. Data represent mean 6 SEM (n 5 4). The statistical significance was established by 1-way ANOVA
followed by Bonferroni’s correction (*P , .05; **P , .01; ***P , .001).
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responses in immune cells including monocytes,16 mast cells,37
eosinophils, and neutrophils.38 Moreover, the involvement of LL37
in the development of pathological conditions such as sepsis,
inflammatory bowel disease, psoriasis, and cystic fibrosis has been
previously reported, and hence, its therapeutic potential has been
analyzed in detail.39 LL37 has also been found to play a role in
the pathogenesis of atherosclerosis,40,41 wherein it leads to the
development of lesions and recruitment of inflammatory cells at the
site of injury.18 However, the role of LL37 in the modulation of
thrombosis and hemostasis has not been investigated until recently.
Immediately prior to the submission of this manuscript, a recent
study demonstrated the functional impact of LL37 in priming
platelets and inducing thromboinflammatory conditions, although
the molecular mechanisms that regulate such effects were not
fully established.21 However, in this study, we have investigated the
impact of LL37 in the modulation of platelet reactivity, thrombosis,
and hemostasis under physiological conditions and uncovered the
functional dependence of LL37 on FPR2/ALX in platelets.
The expression of LL37 has been reported in numerous cell types
including epithelial cells and immune cells such as neutrophils
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and monocytes.42 Because platelets are also derived from the
myeloid lineage,43 we hypothesized that platelets may possess
LL37, and indeed the presence of LL37 in platelets and its
release to the external milieu upon activation were confirmed in
this study. Similar to neutrophils, platelets may also contain LL37
in their granules and release it upon stimulation to increase its
concentration at the local environment and enhance the second-
ary activation of platelets toward augmentation of thrombosis.
A recent study21 also reported the elevated level of LL37 in
the microenvironment of arterial thrombi in human and mice.
Platelets are known to contain several antimicrobial peptides
and release them upon activation during microbial infection.44
Similarly, platelets may contribute to the release of LL37 upon
activation to support the microbial clearance, activation of in-
flammatory responses, and modulation of thrombosis and hemo-
stasis during pathological settings. Although the activation of
platelets during inflammatory diseases is inevitable because of the
presence of several molecules that activate platelets,45 here we
demonstrate LL37 as a major contributor to platelet activation and
thrombus formation.
Thrombosis and subsequent bleeding are associated with various
inflammatory diseases.46 Similarly, disseminated intravascular co-
agulation, thrombosis in the microvasculature, and sequestration
of platelets are some of the common clinical manifestations in
sepsis.47 The level of LL37 is significantly increased in psoriasis48
and sepsis49 patients compared with healthy individuals. In line
with thrombosis in vasculature, LL37 augmented in vitro thrombus
formation and shortened the bleeding time in mice. These data
demonstrate a fundamental function for LL37 in the modulation
of thrombosis and hemostasis. Similarly, LL37 induced platelet
aggregation, fibrinogen binding, granule secretion, adhesion,
spreading, and intracellular calcium mobilization in platelets. Pircher
et al21 also demonstrated the functional impact of LL37 on arterial
thrombosis and platelet granule secretion. In line with this previous
study, we also did not observe the ability of LL37 to induce platelet
aggregation in PRP, although it displayed aggregation in human
isolated platelets. Similarly, the previous study has failed to detect
a response for LL37 on integrin aIIbb3 activation and platelet
spreading on a fibrinogen-coated surface. In our study, however,
we demonstrate the ability of LL37 to increase fibrinogen binding
and platelet spreading. Surprisingly, the previous study failed
to detect integrin aIIbb3 activation. However, we have directly
measured the level of fibrinogen binding in isolated platelets,
PRP, and whole blood with a range of concentrations of LL37
(ie, up 50 mM), whereas they have measured PAC-1 binding in
isolated platelets using LL37 concentrations of only up to 5 mM.
It is unclear why these discrepancies occur between the
previously reported data and our results, although it may be
attributed in part to the differences in the methodologies used.
The concentrations used in this study (up to 50 mM) revealed
the activatory effects of LL37 in platelets. A recent study reported
the inhibitory effects of LL37 in platelets at concentrations between
0.1 and 1.2 mM.28 These concentrations are not only substantially
greater than those achievable in pathological conditions, but also
exert cytotoxic effects in several cell types29 including platelets
(Figure 2E) at 100 mM. However, in severe psoriasis, a median
concentration of 304 mM LL37 in psoriatic lesions has been
reported,48 which can exert cytotoxicity towards platelets at the
local sites and reduce the number of functional platelets. During
pulmonary infection, a concentration of 5 mM LL37 has been
detected.50 Notably, the normal plasma concentration of LL37 in
healthy individuals is suggested to be ;1.2 mM,51 which did not
exert any effects on platelets. The LL37 concentrations used in
this study are similar to those achievable during pathological
conditions, such as sepsis,49 and early stages of psoriasis. Hence,
the LL37 inhibitory effects previously reported in platelets may
well be because of cytotoxicity, although additional causes cannot
be excluded. This perspective was also reflected in the recent
study by Pircher et al.21 Together with the previous reports, our
data demonstrate that LL37 induces platelet activation at the
early stages of inflammatory diseases resulting in the initiation
of thrombosis and modulation of hemostasis. However, at concen-
trations of 100 mM and above, LL37 may exert cytotoxicity, reducing
the number and function of circulating platelets, which can ultimately
lead to bleeding complications. Together with the modulation of
thrombosis and hemostasis, LL37 may also induce other platelet-
related complications (eg, thrombocytopenia and inflammation)
during various inflammatory diseases where its level is elevated.
Notably, the previous study21 has demonstrated the impact of
LL37 in the augmentation of platelet-neutrophil interactions, cytokine
release, release of extracellular nucleosomes, and reactive oxygen
species.
LL37 has been reported to act mainly through FPR2/ALX in other
cell types,16,24 although additional receptors such as Toll-like
receptors, receptor tyrosine kinases, ligand-gated ion channel,
CCR3, P2Y11, and P2X7 were shown to bind this peptide.
52 To
investigate the underlying molecular mechanisms through which
LL37 modulates platelet function, the effects of LL37 in human
platelets treated with WRW4 and platelets obtained from Fpr2/3
2/2
mice were analyzed. LL37-mediated activation was largely re-
duced by WRW4 and in platelets obtained from Fpr2/3
2/2 mice,
confirming the functional dependence of LL37 primarily on FPR2/
ALX. LL37 binding assays confirmed the substantial reduction in
the binding of LL37 to Fpr2/32/2 platelet surface compared with
Fpr12/2 and control mouse platelets. Additionally, we were able
Table 1. Summary of polar contacts between LL37 and FPR2/ALX
Hydrogen bond interactions
Interacting LL37
residues
Interacting FPR2/ALX
residues
Average distance
(A˚)
Gly-3 (N) Arg-26 (NH2) 2.76
Ser-9 (OG) Glu-89 (OE1) 3.12
Ser-9 (O) Glu-89 (OE2) 2.61
Lys-10 (N) Glu-89 (OE2) 2.81
Ser-9 (OG) Asn-171 (ND2) 3.00
Gln-22 (NE2) Ser-182 (N) 3.20
Gln-22 (OE1) Ser-182 (OG) 2.91
Gln-22 (NE2) Ser-182 (OG) 3.14
Gln-22 (NE2) Ser-182 (OG) 3.18
Glu-11 (OE2) Gly-275 (N) 3.23
Lys-8 (NZ) Lys-276 (O) 2.53
Arg-7 (NH1) Asn-285 (OD1) 3.08
Arg-7 (NE) Asn-285 (OD1) 3.29
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to demonstrate that FPR2/ALX inhibition in human platelets or
deletion of Fpr2/3 gene in mice lead to the elevation of cAMP
levels, which is a major inhibitory molecule for platelet activation.
This indicates the involvement of cAMP-dependent signaling
pathways in the regulation of FPR2/ALX in platelets. Nevertheless,
the activation of platelets by LL37 through receptors other than
FPRs cannot be excluded, and further investigations will be
needed to explore the contributions of such receptors in the
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represent mean 6 SEM (n 5 3). P values shown are as calculated by 2-way ANOVA followed by Bonferroni’s correction in most of the experiments except for the data shown
in panels A-C, which were analyzed by 1-way ANOVA followed by Bonferroni’s correction (*P , .05; **P , .01).
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modulation of platelet function upon ligation with LL37. In-
terestingly, the recent study21 has reported that LL37 is partially
acting through the GPVI signaling pathway in platelets, but it does
not have any impact on G protein-coupled receptor–mediated
signaling specifically via FPR1 and FPR2/ALX using a single
concentration of pharmacological inhibitors (Boc-MLF and
WRW4) for these receptors. However, in the present study, we
report the presence of FPR2/ALX (a G protein-coupled receptor)
and its role in the regulation of LL37-mediated effects in platelets
using a range of concentrations of these pharmacological
inhibitors and platelets obtained from Fpr2/32/2 mice in multiple
experiments.
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In conclusion, we demonstrate that LL37 is stored in platelets and
secreted upon activation. Similar to a recent publication,21 we also
report that LL37 promotes thrombus formation. LL37 induced a
range of platelet function such as platelet aggregation, inside-out
signaling to integrin aIIbb3 and outside-in signaling, granule
secretion, calcium mobilization, and shortened tail bleeding time
in mice. These effects were diminished in the presence of an
FPR2/ALX pharmacological inhibitor and in platelets obtained
from Fpr2/32/2 mice confirming the functional dependence of
LL37 primarily via this receptor in platelets. Additionally, we
demonstrate an instrumental role for FPR2/ALX in the positive
feedback regulation of platelet function, in which the deficiency
or blockade of this receptor impaired hemostasis and the normal
activation of platelets. The significant roles of LL37 and FPR2/
ALX in the modulation of thrombosis and hemostasis renders
them potential candidates for the exacerbation of platelet-related
complications and immune responses in numerous inflammatory
diseases where platelets play critical roles. Notably, the pres-
ence of FPRs in platelets opens up new avenues to investigate
the involvement of a multiplicity of FPR ligands in the modulation
of thrombosis, hemostasis, and other platelet-related compli-
cations during inflammatory responses. Based on the data
presented in this study, both LL37 and FPRs can act as potential
therapeutic targets for cardiovascular and a range of inflamma-
tory diseases.
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